#abbvie

[ follow ]
#pfizer
from24/7 Wall St.
2 days ago
Business

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat - The Other Is Praying for a Pipeline Hit

AbbVie reported record net sales driven by Skyrizi and Rinvoq, while Pfizer faced revenue decline due to COVID-related impacts.
from24/7 Wall St.
1 week ago
Business

High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout

AbbVie shows strong growth with Skyrizi, while Pfizer struggles with declining COVID revenue and sustainability concerns in dividends.
Business
from24/7 Wall St.
2 days ago

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat - The Other Is Praying for a Pipeline Hit

AbbVie reported record net sales driven by Skyrizi and Rinvoq, while Pfizer faced revenue decline due to COVID-related impacts.
Business
from24/7 Wall St.
1 week ago

High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout

AbbVie shows strong growth with Skyrizi, while Pfizer struggles with declining COVID revenue and sustainability concerns in dividends.
Business
from24/7 Wall St.
1 week ago

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

JPMorgan maintains an Overweight rating on AbbVie, viewing recent stock pullback as a buying opportunity with a $260 price target.
#dividend-stocks
Healthcare
from24/7 Wall St.
4 months ago

This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence

Healthcare shows signs of stabilization and potential rebound driven by easing policy risks, clearer earnings, and increased M&A, with AbbVie as a dividend-led candidate.
#dividend-investing
Medicine
from24/7 Wall St.
6 months ago

Top Dividend Stocks Poised for Explosive Growth in 2026 (ABBV, GD, RGR)

AbbVie shows strong stock performance near analyst targets, offers a 2.79% dividend yield, and markets a novel C‑MET–targeting oncology drug, Emrelis.
[ Load more ]